Drug intelligence / Profile preview

Emploem Extended-Release Tablet

Development stage: Phase 4
Lead developer: Dracen Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

DKP104, marketed as Emploem Extended-Release Tablet, is an improved new drug (개량신약) developed by Dongkwang for the management of type 2 diabetes mellitus. It is a fixed-dose combination of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride, a biguanide, formulated as an oral extended-release tablet. Empagliflozin works by inhibiting SGLT2 in the proximal renal tubules, thereby reducing renal glucose reabsorption and increasing urinary glucose excretion. Metformin primarily lowers blood glucose by decreasing hepatic glucose production and improving peripheral insulin sensitivity. This combination therapy is designed to provide complementary mechanisms of action for glycemic control in a convenient once-daily dosing regimen. DKP104 received regulatory approval in South Korea in 2024.

Brand names: Emploem Extended-Release Tablet엠플로엠서방정
Other names: Emploem Extended-Release Tablet 10/1000엠플로엠서방정10/1000Emploem XR

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)ALB (Human serum albumin)SGLT2 (Sodium-glucose cotransporter protein subunit 2)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on Emploem Extended-Release Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emploem Extended-Release Tablet.